Intravitreal aflibercept for the treatment of chronic central serous chorioretinopathy

Poster Details

First Author: P.Ozdal TURKEY

Co Author(s):    K. Tekin   B. Gulpamuk   M. Teke                       

Abstract Details


To evaluate the efficacy and tolerability of intravitreal aflibercept injection as a treatment option in eyes with chronic central serous chorioretinopathy (CSCR).


A single-centre prospective interventional study conducted in an specialized eye hospital which is a tertiary referral centre.


10 eyes of 10 patients with chronic CSCR who had been followed for > 6 months after the first intravitreal injection of aflibercept were recruited for the study. The best corrected visual acuity (BCVA) and central macular thickness (CMT) values obtained by spectral-domain optical coherence tomography were recorded at baseline and the first, third, and sixth months after the injection.


The mean LogMAR BCVA was 0.70 ± 0.25 at the baseline. At the first, third, and sixth months after the injection, the mean LogMAR BCVA values were 0.39 ± 0.36, 0.32 ± 0.39 and 0.29 ± 0.34 respectively. The mean BCVA during the entire follow-up period was significantly improved compared with the baseline BCVA. Complete or partial resolution of subretinal fluid (SRF) was observed in all patients. SRF resolved completely in five (50%) and partially in 3 (30%) patients in whom additional aflibercept injection(s) were needed. Two patients recurred approximately 4 months after the baseline. In one of these 2 patients, SRF resolved completely after applying focal laser photocoagulation to the leakage area. The mean CMT was 449.30 ± 142.53 μm at baseline and was measured as 302.60 ± 72.28 μm on the first month, 294.30 ± 72.85 μm on the third, and 294.60 ± 83.84 μm on the sixth month post-injection. The mean CMT during the entire follow-up period decreased significantly compared with the baseline CMT. No patients experienced any serious ocular or systemic adverse events over the course of the study.


Intravitreal aflibercept is an effective and well-tolerated agent to improve the BCVA and reduce the CMT in patients with chronic CSCR.

Back to previous
EURETINA, Temple House, Temple Road, Blackrock, Co Dublin. | Phone: 00353 1 2100092 | Fax: 00353 1 2091112 | Email:

Privacy policyHotel Terms and Conditions Cancellation policy